Add like
Add dislike
Add to saved papers

Limbal allograft, amniotic membrane transplantation, and intraoperative mitomycin C for recurrent pterygium.

Ophthalmology 2005 July
OBJECTIVE: To conduct a pilot study evaluating the efficacy and safety of limbal allograft, preserved amniotic membrane transplantation, and intraoperative mitomycin C treatment for recurrent pterygium.

DESIGN: Prospective, noncomparative, interventional case series.

PARTICIPANTS: Twelve eyes of 11 patients with recurrent pterygium. The mean number of previous surgeries for pterygium was 1.9+/-1.4 (range, 1-6).

INTERVENTION: All subjects received limbal allograft, preserved amniotic membrane transplantation, and intraoperative mitomycin C.

MAIN OUTCOME MEASURES: Pterygium recurrence and complications.

RESULTS: The mean follow-up period was 21.6+/-5.6 months (range, 16-36 months). There was no pterygium recurrence in any of the eyes. Symblepharon reappeared in 3 eyes and diplopia recurred in 2 eyes. There were no other surgical complications and there was no graft rejection.

CONCLUSIONS: Limbal allograft, preserved amniotic membrane transplantation, and intraoperative mitomycin C may be a safe and effective procedure for recurrent pterygium.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app